Dataset Information

ABCA7 transporter functional role on Alzheimer’s disease onset and progess

ABSTRACT: Identification of new drug targets and biomarkers with a true clinical potential to treat or at least modify the disease course of Alzheimer’s disease (AD) has become a major challenge. Despite newly identified, GWAS-derived risk factors for AD, this type of genetic information only represents the surface layer of a deep multidimensional network impacting ND pathogenesis. GWAS studies have recently highlight ABCA7 transporter as a risk marker for AD. We will assess existing and newly generated large-scale targeted proteomics data from animal cohorts to unravel the interplay and interactions of metabolites, lipids and proteins contributing to ABCA7-related disease pathogenesis. We want to understand the complex and multi-factorial mechanisms taking place at the metabolism level – including regulatory and signaling aspects – that contribute to AD onset and progression. By doing so, we will enable the identification of more drugable targets that are linked to this risk factor activity and open up novel starting points for pharmacological interventions and possibly prevention. Our work will also allow for a better disease understanding and the identification of novel metabolic biomarkers, which may help in disease monitoring and patient stratification for clinical

INSTRUMENT(S): timsTOF Pro

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): Brain

SUBMITTER: Jens Pahnke

LAB HEAD: Jens Pahnke

PROVIDER: PXD053250 | Pride | 2025-05-07

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	LC_MS_file.7z	Other
	mqpar.xml	Xml
	txt.7z	Other

Items per page:

1 - 3 of 3

Publications

The ABC transporter A7 modulates neuroinflammation via NLRP3 inflammasome in Alzheimer's disease mice.

Santos-García Irene I Bascuñana Pablo P Brackhan Mirjam M Villa María M Eiriz Ivan I Brüning Thomas T Pahnke Jens J

Alzheimer's research & therapy 20250127 1

<h4>Background</h4>Specific genetic variants in the ATP-binding cassette transporter A7 locus (ABCA7) are associated with an increased risk of Alzheimer's disease (AD). ABCA7 transports lipids from/across cell membranes, regulates Aβ peptide processing and clearance, and modulates microglial and T-cell functions to maintain immune homeostasis in the brain. During AD pathogenesis, neuroinflammation is one of the key mechanisms involved. Therefore, we wanted to investigate the specific role of ABC ...[more]

PMID: 39871385

Similar Datasets

Project description:Background & Aims: Cholangiocarcinomas (CCAs), heterogeneous biliary tumors with dismal prognosis, lack accurate early-diagnostic methods, especially important for individuals at high-risk (i.e., primary sclerosing cholangitis (PSC)). Here, we searched for protein biomarkers in serum extracellular vesicles (EVs). Methods: EVs from patients with isolated PSC (n=45), concomitant PSC-CCA (n=42), PSC who developed CCA during follow-up (PSC to CCA; n=25), CCAs from non-PSC etiology (n=56), hepatocellular carcinoma (n=34) and healthy individuals (n=55) were characterized by mass-spectrometry. Diagnostic biomarkers of PSC-CCA, non-PSC CCA or CCAs regardless etiology (pan-CCAs) were defined, and their expression was evaluated in human organs/tissues and within CCA tumors at single-cell level. Prognostic EV-biomarkers for CCA were investigated. Results: High-throughput proteomics identified candidate diagnostic biomarkers for PSC-CCA, non-PSC CCA or pan-CCA, as well as and for differential diagnosis of intrahepatic CCA and HCC, that were cross-validated by ELISA using total serum. Machine learning logit modelling disclosed CRP/FRIL/Fibrinogen algorithm with diagnostic value for early-stage PSC-CCA vs isolated PSC (AUC=0.944; OR=82.0), overpowering CA19-9 (AUC=0.735; OR=9.3). An algorithm combining CRP/VWF/PIGR/ /Fibrinogen allowed the diagnosis of early-stage non-PSC CCAs compared to healthy individuals (AUC=0.999; OR=1115). Noteworthy, levels of Fibrinogen/CRP/PIGR/FRIL showed predictive capacity for CCA development in patients with PSC before clinical evidences of malignancy. Multi-organ transcriptomic analysis revealed that serum EV-biomarkers were mostly expressed in hepatobiliary tissues, and scRNA-seq and immunofluorescence analysis of CCA tumors showed their presence mainly in malignant cholangiocytes. Multivariable analysis unveiled EVprognostic biomarkers independent to clinical features, with COMP/GNAI2/CFAI and ACTN1/MYCT1/PF4V associated negatively or positively to patients’ survival, respectively. Conclusions: Serum EVs contain protein biomarkers for the prediction, early diagnosis and prognosis estimation of CCA, representing a novel tumor cell-derived liquid biopsy for personalized medicine.